Combination Therapy Incorporating 3 New Agents Shows Promise as Treatment for Aggressive Lymphoma
Wednesday, April 20, 2016 - 02:50
in Health & Medicine
New research from Roswell Park Cancer Institute (RPCI) shows that promising cancer drugs used in combination can have significant therapeutic impact on a particularly aggressive subtype of diffuse large B-cell lymphoma (DH-DLBCL) in preclinical studies. The researchers will present their findings at the American Association for Cancer Research (AACR) Annual Meeting 2016, to be held April 16-20 in New Orleans.